Insulet Corporation

Insulet Corporation designs and manufactures tubeless, wearable automated insulin delivery systems for people with diabetes. Founded in 2000, the company has spent more than two decades developing its Omnipod platform, from an initial concept sketch to a commercial technology serving over 600,000 customers across 25 countries. It is publicly traded on NASDAQ under the ticker PODD and reported revenue of $2.1 billion.

The company's technical work spans medical devices, wearable technology, automated insulin delivery, smartphone-controlled device connectivity and drug delivery. Its flagship product, Omnipod, is a tubeless wearable insulin delivery system. Omnipod 5, the world's first tubeless automated insulin delivery system controlled by a smartphone, is the #1 prescribed automated insulin delivery system in the United States.

Insulet operates across North America, Europe, the Middle East and Asia Pacific, within the diabetes management, healthcare and medical devices sectors. The company traces its origins to a father's attempt to spare his son daily insulin injections, and describes its mission as making diabetes a smaller part of life, with an emphasis on simplicity, freedom and better outcomes for its customer community, known as "Podders".